Skip to main content
AAN.com
Articles
November 1, 1996

Treatment of four siblings with progressive myoclonus epilepsy of the Unverricht-Lundborg type with N-acetylcysteine

November 1996 issue
47 (5) 1264-1268

Abstract

The finding of increased activity of the enzyme extracellular superoxide dismutase in four siblings with progressive myoclonus epilepsy of the Unverricht-Lundborg type (PME-UL) prompted the addition of antioxidants to these patients' treatment regimen. After 6 months treatment with vitamin E, selenium, riboflavin, and zinc, there was some improvement in patient awareness and speech. N-acetylcysteine (NAC) is a sulfhydryl antioxidant that increases cellular glutathione and the activity levels of several antioxidant enzymes and has additional actions that contribute to its demonstrated efficacy in preventing or decreasing damage in models of neuronal toxicity. We treated the affected siblings with 4 to 6 grams a day of NAC in addition to the other antioxidants and magnesium. There has been a marked decrease in myoclonus and some normalization of somatosensory evoked potentials with NAC treatment. The patients were treated with NAC for up to 30 months with continued beneficial effects. NAC may prevent further deterioration in the clinical course of patients with PME-UL and may be indicated in other neurodegenerative conditions where excess free radical activity may contribute to disease progression.
NEUROLOGY 1996;47: 1264-1268.

Get full access to this article

View all available purchase options and get full access to this article.

REFERENCES

1.
Marseille Consensus Group. Classification of progressive myoclonus epilepsies and related disorders. Ann Neurol 1990;28:113-116.
2.
Eldridge R, Iivanainen M, Stern R, Koerber T, Wilder BJ. "Baltic" myoclonus epilepsy: hereditary disorder of childhood made worse by phenytoin. Lancet 1983;2:838-842.
3.
Lehesjoki AE, Koskiniemi M, Pandolfo M, et al. Linkage studies in progressive myoclonus epilepsy: Unverricht-Lundborg and Lafora diseases. Neurology 1992;42:1545-1550.
4.
Lehesjoki AE, Eldridge R, Eldridge J, Wilder BJ, de la Chapelle A. Progressive myoclonus epilepsy of the Unverricht-Lundborg type: a clinical and molecular genetic study of a family from the United States with four affected sibs. Neurology 1993;43:2384-2386.
5.
Yamakawa K, Mitchell S, Hubert R, et al. Isolation and characterization of a candidate gene for progressive myoclonus epilepsy on 21q22.3. Hum Mol Genet 1995;4:709-716.
6.
Hurd RW, Wilder BJ, Perchalski, RJ. Increased extracellular superoxide dismutase in Baltic myoclonus [abstract]. Epilepsia 1993;34(Suppl 2):14-15.
7.
Levanon D, Lieman-Hurwitz J, Dafni W, et al. Architecture and anatomy of the chromosomal locus in human chromosome 21 encoding the Cu/Zn superoxide dismutase. EMBO J 1985;4:77-84.
8.
Oury TD, Ho Y-S, Piantadosi CA, Crapo JD. Extracellular superoxide dismutase, nitric oxide, and central nervous system toxicity. Proc Natl Acad Sci USA 1992;89:9715-9719.
9.
Aruoma OI, Halliwell B, Hoey BM, Butler J. The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic Biol Med 1989;6:593-597.
10.
Godson C, Ryan MD, Brady HR, Bourke S, Fitsgerald MX. Acute hypomagnesaemia complicating the treatment of meconium ileus equivalent in cystic fibrosis. Scand J Gastroenterol 1988;143(Suppl):148-150.
11.
Berkovic SF, So NK, Andermann F. Progressive myoclonus epilepsies: clinical and neurophysiological diagnosis. J Clin Neurophysiol 1991;8:261-274.
12.
Gotz ME, Kunig G, Riederer P, Youdim MBH. Oxidative stress: free radical production in neural degeneration. Pharmacol Ther 1994;63:37-122.
13.
Hendrickson DJ, Fisher JH, Jones C, Ho YS. Regional localization of human extracellular superoxide dismutase gene to 4pter-q21. Genomics 1990;8:736-738.
14.
Sandstrom J, Nilsson P, Karlsson K, Marklund SL. 10-fold increase in human plasma extracellular superoxide dismutase content caused by a mutation in heparin-binding domain. J Biol Chem 1994;269:19163-19166.
15.
Hurd RW, Perchalski RJ, Wilder BJ, Uthman BM, Pippenger CE. The role of copper in the differing effects of valproic acid (VPA) and phenytoin (PHT) in progressive myoclonus epilepsy of the Unverricht-Lundborg type (PME-UL) [abstract]. Neurology 1994;44(Suppl 2):A295.
16.
Taylor A, Ghose K. Diurnal variation of serum copper and zinc in epileptics receiving anticonvulsants. Hum Toxicol 1986;5:195-200.
17.
Sorenson JRJ. Copper complexes offer a physiological approach to treatment of chronic diseases. Prog Med Chem 1989;26:439-568.
18.
Pippenger CE, Meng X, Rothner D, et al. Free radical scavenging enzyme activity profiles in risk assessment of idiosyncratic drug reactions. In: Levy RH, Penry JK, eds. Idiosyncratic reactions to valproate: clinical risk patterns and mechanisms of toxicity. New York: Raven Press, 1991:75-88.
19.
Kelloff DS, Crowell JA, Boone CW, et al. Clinical development plan: N-acetylcysteine (NAC). J Cell Biochem Suppl 1994;20(Suppl 20):63-73.
20.
Ziment I. Acetylcysteine: a drug that is much more than a mucokinetic. Biomed Pharmacother 1988;42:513-520.
21.
Roederer M, Staal FJ, Ela JW, Herzenberg LA, Herzenberg LA. N-acetylcysteine: potential for AIDS therapy. Pharmacology 1993;46:121-129.
22.
Cossarizza A, Franceschi C, Monti D, et al. Protective effect of N-acetylcysteine in tumor necrosis factor- alpha -induced apoptosis in U937 cells: the role of mitochondria. Exp Cell Res 1995;20:232-240.
23.
Zhang H, Spapen H, Nguyen DN, Benlabed M, Buurman WA, Vincent J-L. Protective effects of N-acetyl-L-cysteine in endotoxemia. Am J Physiol 1994;266:H1746-H1754.
24.
Mayer M, Noble M. N-acetyl-L-cysteine is a pluripotent protector against cell death and enhancer of trophic factor-mediated cell survival in-vitro. Proc Natl Acad Sci USA 1994;91:7496-7500.
25.
Ratan RR, Murphy TH, Baraban JM. Oxidative stress induces apoptosis in embryonic cortical neurons. J Neurochem 1994;62:376-379.
26.
Ferrari G, Yan CYI, Greene LA. N-Acetylcysteine (D- and L-stereoisomers) prevents apoptic death of neuronal cells. J Neurosci 1995;15:2857-2866.
27.
Henderson P, Hale TW, Sherm S, Habersang RW. N-Acetylcysteine therapy of acute heavy metal poisoning in mice. Vet Hum Toxicol 1985;27:522-525.
28.
Boesgaard S, Aldershvile J, Poulsen HE, Christensen S, Dige-Petersen H, Giese J. N-Acetylcysteine inhibits angiotensin converting enzyme in vivo. J Pharmacol Exp Ther 1993;265:1239-1244.

Information & Authors

Information

Published In

Neurology®
Volume 47Number 5November 1996
Pages: 1264-1268
PubMed: 8909441

Publication History

Published online: November 1, 1996
Published in print: November 1996

Permissions

Request permissions for this article.

Authors

Affiliations & Disclosures

Wendell R. Helveston, MD
From the Neurology Service, Gainesville Veterans Affairs Medical Center and Department of Neurology, University of Florida, Gainesville, FL.
Supported by the Epilepsy Research Foundation of Florida, Inc.
Received July 8, 1994. Accepted in final form April 3, 1996.
Address correspondence and reprint requests to Dr Wilder, Professor Emeritus of Neurology, Department of Neurology, Box 100236, University of Florida College of Medicine, Gainesville, FL 32610.

Metrics & Citations

Metrics

Citation information is sourced from Crossref Cited-by service.

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Neuroinflammation and Epilepsy: From Pathophysiology to Therapies Based on Repurposing Drugs, International Journal of Molecular Sciences, 25, 8, (4161), (2024).https://doi.org/10.3390/ijms25084161
    Crossref
  2. Drug arrows in the quiver-antiseizure, antiepileptic and neuroprotective medication: Treatment and future aspects. A focused review, Seizure: European Journal of Epilepsy, (2024).https://doi.org/10.1016/j.seizure.2024.11.016
    Crossref
  3. Increasing glutathione levels by a novel posttranslational mechanism inhibits neuronal hyperexcitability, Redox Biology, 67, (102895), (2023).https://doi.org/10.1016/j.redox.2023.102895
    Crossref
  4. N-acetylcysteine aggravates seizures while improving depressive-like and cognitive impairment comorbidities in the WAG/Rij rat model of absence epilepsy, Molecular Neurobiology, 59, 5, (2702-2714), (2022).https://doi.org/10.1007/s12035-021-02720-3
    Crossref
  5. Progressive myoclonic epilepsies—English VersionProgressive Myoklonusepilepsien – Englische Version, Zeitschrift für Epileptologie, 35, S2, (127-131), (2022).https://doi.org/10.1007/s10309-022-00546-0
    Crossref
  6. Progressive MyoklonusepilepsienProgressive myoclonic epilepsies, Clinical Epileptology, 36, 3, (238-243), (2022).https://doi.org/10.1007/s10309-022-00524-6
    Crossref
  7. Altered Expression of Peroxiredoxins in Mouse Model of Progressive Myoclonus Epilepsy upon LPS-Induced Neuroinflammation, Antioxidants, 10, 3, (357), (2021).https://doi.org/10.3390/antiox10030357
    Crossref
  8. New Trends and Most Promising Therapeutic Strategies for Epilepsy Treatment, Frontiers in Neurology, 12, (2021).https://doi.org/10.3389/fneur.2021.753753
    Crossref
  9. Myoclonus, Principles and Practice of Movement Disorders, (495-512.e7), (2021).https://doi.org/10.1016/B978-0-323-31071-0.00018-4
    Crossref
  10. The acute effect of metabolic cofactor supplementation: a potential therapeutic strategy against non‐alcoholic fatty liver disease, Molecular Systems Biology, 16, 4, (2020).https://doi.org/10.15252/msb.209495
    Crossref
  11. See more
Loading...

View Options

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

View options

PDF and All Supplements

Download PDF and Supplementary Material

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Figures

Tables

Media

Share

Share

Share article link

Share